Table 4.

Safety [%, n] in the overall population [n = 350].

Adverse events	44.8% [157]
Serious adverse events	8.6% [30]
-infections	23.3% [7]
-allergic reactions	26.7% [8]
-psoriasiform lesions	13.3% [4]
-unspecific skin lesions	6.7% [2]
-others	30.0% [9]
Non-serious adverse events	36.3% [127]
-infections	33.9% [43]
-allergic reactions	8.7% [11]
-psoriasiform lesions	10.2% [13]
-unspecific skin lesions	22.0% [28]
-others	25.2% [32]